FDA Expands Approval of Oral Diabetes Drug Rybelsus to Reduce Cardiovascular Risk
Table of Contents
A new FDA approval offers a significant advancement in the treatment of type 2 diabetes, extending the therapeutic indication of Rybelsus (oral semaglutide) to include a reduction in the risk of major adverse cardiovascular events (MACE). The decision impacts adults with type 2 diabetes who are at increased risk for these events, regardless of prior history.
The FDA’s move, announced Thursday, centers on data from the phase 3 SOUL clinical trial, which demonstrated a substantial benefit for patients. This approval positions Rybelsus as the sole oral glucagon-like peptide-1 (GLP-1) drug authorized to lower MACE risk in this high-risk patient population.
Addressing a Critical Need: Diabetes and Cardiovascular Health
Major adverse cardiovascular events encompass serious conditions like myocardial infarction (heart attack) and stroke. The FDA’s expanded approval recognizes the heightened cardiovascular risk faced by individuals with type 2 diabetes. “Even in the absence of a previous heart attack or stroke, adults with type 2 diabetes are at increased risk for cardiovascular events, underscoring the need for therapies that go beyond glycemic control,” stated a leading expert involved in the SOUL study.
This expanded indication covers both primary prevention – reducing risk in those without a prior cardiovascular event – and secondary prevention – lowering the risk of subsequent events in individuals with existing cardiovascular disease.
SOUL Trial Results Demonstrate Significant Benefit
The SOUL trial specifically evaluated the impact of oral semaglutide 14 mg, used in conjunction with standard care, on MACE risk in adults with type 2 diabetes. The results, considered statistically significant, revealed a 14% reduction in the risk of MACE over a four-year period compared to a placebo group. Importantly, the drug’s safety profile remained consistent with findings from previous studies.
Rybelsus initially received FDA authorization in 2019 as a treatment to improve glycemic control in adults with type 2 diabetes, when combined with diet and exercise. This latest approval broadens its therapeutic role considerably.
Global Regulatory Momentum
The positive regulatory trend isn’t limited to the United States. Last month, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) also issued a favorable opinion regarding a similar expansion of Rybelsus’s indication within the European Union. This suggests a growing international consensus on the drug’s cardiovascular benefits.
This expanded approval of Rybelsus represents a crucial step forward in holistic diabetes management, offering a convenient oral therapy option to address a leading cause of morbidity and mortality among those living with type 2 diabetes.
